At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.

The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.

Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.

Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.

A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.

Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 

Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.

The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.